nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.09.2012 | Review Article

Antiangiogenic therapy in the management of brain tumors: a clinical overview

verfasst von: Saroj Kunnakkat, Maya Mathew, Ashwatha Narayana

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Central to the process of brain tumor development is angiogenesis, which involves a host of molecules and receptors. In recent years, antiangiogenic therapies have been developed and tested for their effectiveness against these tumors. Among them are inhibitors against vascular endothelial growth factor and its receptors, as well as inhibitors targeting the platelet-derived growth factor family, integrins, and histone deacetylase. While many have been shown to be effective with limited toxicity, some tumors are able to adopt escape mechanisms. Further research is needed in the development of effective multi-targeted agents to reduce these effects.

Fidler IJ (1999) Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmaco 43:S3–S10CrossRef

Jiménez B, Volpert OV (2001) Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 78(12):663–672PubMedCrossRef

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027PubMedCrossRef

Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19(10):2003–2012PubMedCrossRef

Bautch VL, Redick SD, Scalia A, Harmaty M, Carmeliet P, Rapoport R (2000) Characterization of the vasculogenic block in the absence of vascular endothelial growth factor-A. Blood 95(6):1979–1987PubMed

Fong G-H, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376(6535):66–70PubMedCrossRef

Shalaby F, Rossant J, Yamaguchi TP et al (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535):62–66PubMedCrossRef

Zagzag D, Amirnovin R, Greco MA et al (2000) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80(6):837–849PubMedCrossRef

Zagzag D, Lukyanov Y, Lan L et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12):1221–1232PubMedCrossRef

10.

Vredenburgh J, Desjardins A, Herndon J et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729PubMedCrossRef

11.

Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740PubMedCrossRef

12.

Nghiemphu PL, Liu W et al (2009) Bevacizumab and chemotherapy for recurrent glioblastoma. Neurology 72(14):1217–1222PubMedCrossRef

13.

Kerber M, Reiss Y et al (2008) Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68(18):7342–7351PubMedCrossRef

14.

Geng L, Donnelly E et al (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61(6):2413–2419PubMed

15.

Pietsch T, Valter MM, Wolf HK et al (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93(2):109–117PubMedCrossRef

16.

Caye-Thomasen P et al (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. [Miscellaneous Article]. Otol Neurotol 26(1):98–101PubMedCrossRef

17.

Hoch RV, Soriano P (2003) Roles of PDGF in animal development. Development 130(20):4769–4784PubMedCrossRef

18.

Andrae J, Gallini R et al (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276–1312PubMedCrossRef

19.

Charles N, Ozawa T et al (2010) Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6(2):141–152PubMedCrossRef

20.

Lokker NA, Sullivan CM et al (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells. Cancer Res 62(13):3729–3735PubMed

21.

Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673–687PubMedCrossRef

22.

Zhong J, Paul A et al (2010) Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol 2010(21):430142PubMed

23.

Kanamori M, Kawaguchi T et al (2006) Intracranial microenvironment reveals independent opposing functions of host αVβ3 expression on glioma growth and angiogenesis. J Biol Chem 281(48):37256–37264PubMedCrossRef

24.

Schnell O, Krebs B et al (2008) Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Patho 18(3):378–386CrossRef

25.

Puduvalli V (2001) Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep 3(6):467–475PubMedCrossRef

26.

Weber GF, Ashkar S (2000) Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers. Brain Res Bull 53(4):421–424PubMedCrossRef

27.

Ouaissi M, Ouaissi A (2006) Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2006:13474

28.

Campos B, Bermejo JL et al (2011) Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102(2):387–392PubMedCrossRef

29.

Sharma V, Koul N et al (2010) HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med 14(8):2151–2161PubMedCrossRef

30.

Thudi NK, Shu ST et al (2011) Development of a brain metastatic canine prostate cancer cell line. Prostate 71(12):1251–1263PubMed

31.

Vredenburgh JJ, Desjardins A et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259PubMedCrossRef

32.

Kreisl TN, Kim L et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745PubMedCrossRef

33.

Narayana A, Kelly P et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurgery 110(1):173–180CrossRef

34.

Norden AD, Young GS et al (2008) Bevacizumab for recurrent malignant gliomas. Neurology 70(10):779–787PubMedCrossRef

35.

Lai A, Tran A et al (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2):142–148PubMedCrossRef

36.

Narayana A, Golfinos JG et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Rad Oncol Biol Phys 72(2):383–389CrossRef

37.

Vredenburgh JJ, Desjardins A et al (2012) Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Rad Oncol Biol Phys 82(1):58–66CrossRef

38.

Narayana A, Gruber D et al (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurgery 116(2):341–345CrossRef

39.

Chamberlain MC, Johnston S (2009) Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 115(8):1734–1743PubMedCrossRef

40.

Mautner V-F, Nguyen R et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncol 12(1):14–18PubMedCrossRef

41.

Plotkin SR, Stemmer-Rachamimov AO et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–367PubMedCrossRef

42.

Mautner V-F, Nguyen R et al (2010) Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21(11):2294–2295PubMedCrossRef

43.

Puchner MJA, Hans VH et al (2010) Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 21(12):2445–2446PubMedCrossRef

44.

Goutagny S, Raymond E et al (2011) Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 22(4):990–991PubMedCrossRef

45.

Socinski MA, Langer CJ et al (2009) Safety of bevacizumab in patients with non–small-cell lung cancer and brain metastases. J Clin Oncol 27(31):5255–5261PubMedCrossRef

46.

Labidi SI, Bachelot T et al (2009) Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 9(2):118–121PubMedCrossRef

47.

Wong ET, Huberman M et al (2008) Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26(34):5649–5650PubMedCrossRef

48.

Torcuator R, Zuniga R et al (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neuro-Oncol 94(1):63–68CrossRef

49.

Spratlin JL, Mulder KE et al (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Fut Oncol 6(7):1085–1094CrossRef

50.

Spratlin JL, Cohen RB et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5):780–787PubMedCrossRef

51.

Farrar CT, Kamoun WS et al (2011) Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. PLoS One 6(3):e17228PubMedCrossRef

52.

Dietrich J, Wang D et al (2009) Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 18(10):1549–1557PubMedCrossRef

53.

Batchelor TT, Duda DG et al (2010) Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817–2823PubMedCrossRef

54.

Wachsberger PR, Lawrence YR et al (2012) Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. Int J Rad Oncol Biol Phys 82(1):483–491CrossRef

55.

Siegelin MD, Raskett CM et al (2010) Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett 478(3):165–170PubMedCrossRef

56.

Navis AC, Hamans BC et al (2011) Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. The J Pathol 223(5):626–634CrossRef

57.

Neyns B, Sadones J et al (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neuro-Oncol 103(3):491–501CrossRef

58.

Hainsworth JD, Ervin T et al (2010) Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15):3663–3669PubMedCrossRef

59.

Yoshikawa A, Nakada M et al (2012) Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics. Neuropathol Appl Neurobiol 38(1):105–110PubMedCrossRef

60.

Amaravadi RK, Schuchter LM et al (2009) Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 15(24):7711–7718PubMedCrossRef

61.

Gore ME, Hariharan S et al (2011) Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117(3):501–509PubMedCrossRef

62.

Wuthrick EJ, Kamrava M et al (2011) A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 117(24):5548–5559PubMedCrossRef

63.

Maurer GD, Tritschler I et al (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-Oncol 11(6):747–756PubMedCrossRef

64.

Reardon DA, Fink KL et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610–5617PubMedCrossRef

65.

Stupp R, Hegi ME et al (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712–2718PubMedCrossRef

66.

Sawa H, Murakami H et al (2004) Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 107(6):523–531PubMedCrossRef

67.

Iwamoto FM, Lamborn KR et al (2011) A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American brain tumor consortium study 03–03. Neuro-Oncol 13(5):509–516PubMedCrossRef

68.

Berg SL, Stone J et al (2004) Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol 54(1):85–88PubMedCrossRef

69.

Hariharan S, Gustafson D et al (2007) Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18(8):1400–1407PubMedCrossRef

70.

Shah MH, Binkley P et al (2006) Cardio toxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12(13):3997–4003PubMedCrossRef

71.

Rini BI, Choueiri TK et al (2008) Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113(6):1309–1314PubMedCrossRef

72.

Brunello A, Saia G et al (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44(1):173–175PubMedCrossRef

73.

Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592–603PubMedCrossRef

74.

Lucio-Eterovic AK, Piao Y et al (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15(14):4589–4599PubMedCrossRef

75.

de Groot JF, Fuller G et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncol 12(3):233–242PubMedCrossRef

76.

Iwamoto FM, Abrey LE et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15):1200–1206PubMedCrossRef

77.

Narayana A, Kunnakkat SD et al (2012) Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Rad Oncol Biol Phys 82(1):77–82CrossRef

78.

Wen PY, Macdonald DR et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972PubMedCrossRef

Titel: Antiangiogenic therapy in the management of brain tumors: a clinical overview
verfasst von: Saroj Kunnakkat
Maya Mathew
Ashwatha Narayana
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1926-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Antiangiogenic therapy in the management of brain tumors: a clinical overview

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis

Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer

A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors

Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie